• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Urologix touts five-year study on enlarged prostrate treatment | Research roundup

Urologix touts five-year study on enlarged prostrate treatment | Research roundup

April 27, 2011 By MassDevice staff

Clinical trials roundup

Urologix Inc. (NSDQ:ULGX) is heralding the results of a long-term study on its enlarged prostate treatment device.

Data from a study published in The Journal of Urology show that the Minneapolis-based medical device manufacturer’s Cooled ThermoTherapy (CTT) is safe and effective at treating both symptoms and obstruction associated with benign prostatic hyperplasia (BPH), the company reported.

The study, which was conducted at the Mayo Clinic, University of Texas Southwestern Medical Center and several other medical centers, tracked 96 percent of patients through its duration and showed that CTT treatment results were "well maintained" through 5 years, the company said.

“Durability is the name of the game. The better the results hold up over time, the fewer retreatments and the greater the benefit to cost ratio. In this context, the five-year data from the Urologix Cooled ThermoTherapy Catheter study are very reassuring," University of Texas study investigator Dr. Claus Roehrborn said in prepared remarks.

Only 11 percent of the men in the study went on medication for BPH during the study after treatment with the CTT, according to Urologix. The men in the study group averaged 67 years of age and had an average prostate size of 50 grams, which is typical of men taking one or even two chronic medications for their BPH, the company said.

Here’s a roundup of recent clinical trial and scientific study news:

  • Spray-on skin found effective in burn treatment study
    Avita Medical Ltd. (ASX:AVH) announced that a pilot clinical study of 4 patients suffering from deep dermal flame burns to their legs “healed quickly” following treatment with ReCell Spray-On Skin from Avita Medical in combination with a biological dressing “and were able to return to work and activities of daily living with relative ease.”
    Read more
  • SpinalMotion begins MRI friendly cervical disc study
    SpinalMotion Inc., developer of the investigational Kineflex lumbar and Kineflex |C cervical disc implants for treating degenerative disc disease (DDD), reported that it has started enrolling patients in an international clinical study evaluating the Kineflex|CI cervical artificial disc designed to optimize MRI imaging following disc implantation.
    Read more
  • Regenerative medicine startup Juventas completes phase 1 heart failure trial
    Cleveland Clinic spinoff Juventas Therapeutics successfully completed a phase 1 clinical trial of its regenerative medicine technology in heart failure patients. Cleveland-based Juventas’ technology, JVS-100, works by recruiting stem cells from the bone marrow to create new blood vessels. In addition to heart failure patients, the company is investigating the treatment of patients suffering from critical limb ischemia (CLI), a severe obstruction of the arteries that reduces blood flow to hands, feet or legs, reports MedCity News.
    Read more

  • Study: Evidence-based therapies for STEMI improved survival when used correctly
    There has been a steady increase in the use of evidence-based therapies for the treatment of STEMI in recent years, which has been associated with a large and sustained reduction in mortality, a new Swedish study shows. The study was published in the April 27 issue of the JAMA. In the paper, its researchers note that there is only limited information on the speed of implementation of new evidence-based and guideline-recommended treatments and its association with survival in real-life patients with STEMI, reports HeartWire.
    Read more
  • Health literacy levels help predict mortality in patients with heart failure
    Heart-failure patients with a low degree of health literacy — defined by their self-declared poor ability to read and understand patient-education literature or fill out hospital forms on their own — showed an increased risk of death from any cause in a survey-based cohort study, reports HeartWire.
    Read more
  • Study: Bone suppression significantly increases lung nodule detection
    Riverain Medical announced the publication of a peer-reviewed observer study in the May 2011 issue of the American Journal of Roentgenology. The issue includes research performed at the University of Chicago Medical Center on the ability of radiologists to improve their detection of subtle lung nodules using chest X-rays aided by Riverain Medical’s bone suppression technology. The study showed significant improvements in the physicians’ performance in locating nodules when bone suppression technology was applied.
    Read more
  • BioControl commences study on CardioFit system for HF
    BioControl Medical announced first patient enrollment in the INOVATE-HF (INcrease Of VAgal TonE in Heart Failure) clinical study at Northwest Texas Heart Hospital, Amarillo, Texas, by study investigator Dr. Suresh Neelagaru. INOVATE-HF is a global, multi-center investigational device exemption (IDE) clinical study to determine the safety and efficacy of BioControl Medical’s CardioFit system, an implantable electrical stimulation device designed to improve heart function in patients with congestive heart failure.
    Read more
  • Acucela touts study of dose-dependent visual cycle modulation
    Acucela Inc. announced the publication of a new paper in Retina: The Journal of Retinal and Vitreous Diseases evaluating the safety and tolerability of ACU-4429, a novel, small-molecule visual cycle modulator (VCM). The paper was co-authored by Dr. Ryo Kubota, chairman, president and chief executive officer of Acucela, along with collaborators from Retina Foundation of the Southwest and Otsuka Pharmaceutical, and details the first-time demonstration of a non-retinoid therapeutic in a convenient, oral pill form effectively targeting the visual cycle in a dose-dependent manner.
    Read more

Filed Under: News Well, Research & Development Tagged With: avitamedical, BioControl Medical Ltd., Clinical Trials, Juventas Therapeutics Inc., Riverain Medical, SpinalMotion Inc., Urologix Inc.

In case you missed it

  • How safe is health information after the overturning of Roe?
  • Smith+Nephew opens new plant in Malaysia
  • BD launches combination COVID-19, flu, RSV diagnostic test
  • Zimmer Biomet creates independent nonprofit organization to reduce health disparities
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
  • Nasdaq grants Titan Medical 180-day extension to regain compliance
  • Aerin Medical reports positive 4-year results for VivAer treatment
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
  • How medical device companies are responding to abortion bans
  • Clarius partners with ImaCor on handheld hemodynamic ultrasound tech
  • Withings appoints Elizabeth Coleon as chief marketing officer
  • Visby Medical raises $135M in expanded Series E
  • Boston Scientific to build new plant outside Atlanta
  • NovaXS unveils prototype for smart, needle-free drug delivery device
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
  • SpineX enrolls first patient in spinal neuromodulation technology trial
  • GE Healthcare’s Carescape ventilator battery recall is Class I

RSS From Medical Design & Outsourcing

  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
    Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today. She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during… […]
  • Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
    Cardinal Health (NYSE: CAH) today started air delivery of pharmaceutical products and medical supplies via Zipline drone in North Carolina. San Francisco-based Zipline won FAA Part 135 air carrier certification for the long-range flights earlier this month. The company flew its first commercial deliveries on June 22 with an initial 16-nautical-mile flight. The flights starting… […]
  • Boston Centerless opens manufacturing plant in Indiana
    Boston Centerless announced today that it opened a second manufacturing plant in Fort Wayne, Indiana. Woburn, Massachusetts-based Boston Centerless said in a news release that the latest expansion for the supplier of precision ground bar materials for close tolerance CNC Swiss machining applications represents continued robust growth in key market segments in the Midwest and… […]
  • Dymax strikes new partnership with Quantum Systems
    Rapid curing materials and equipment manufacturer Dymax today announced a new sales partnership with Quantum Systems. Torrington, Connecticut-based Dymax said in a news release that Quantum, with its offices in Arizona as well as Sonora and Baja, Mexico, will focus its efforts on promoting and supporting the sales of Dymax light-curing solutions to the medical,… […]
  • Researchers develop wearable robotic exomuscle system
    ETH Zurich researchers have redefined the muscle shirt. Marie Georgarakis, a former doctoral student at ETH Zurich’s Sensory Motor Systems Lab, is the creator of the Myoshirt, a wearable, textile robotic device that helps users lift their arms and reach. A motorized cable works like an artificial tendon, directed by sensors and an algorithm to… […]
  • They said it at DeviceTalks Boston
    Medtech insiders convened at DeviceTalks Boston 2022 in May to discuss device design, innovation and trends shaping the industry now and in the years and decades ahead. Here are some of the most quotable insights from panelists and speakers at our live event. And make sure to save the date — and save your seat… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS